The MRC BRC and MDU will use funding and cutting-edge research to improve public health until March 2029.
The Medical Research Council (MRC) has awarded two medical research units based at the University of Cambridge a total of £30 million over the next five years.
Scientists from the MRC Biostatistics Unit (BRC) and Metabolic Diseases Unit (MDU) aim to use cutting-edge research to improve public health by March 2029.
Following positive feedback from both units on their achievements and research plans, they will provide a highly effective training environment for skilled researchers across a range of disciplines.
Founded in 1913, the BSU is home to one of the largest groups of biostatisticians in Europe and is a major centre for research, training and knowledge exchange.
This new funding will help further develop, apply and communicate innovative statistical methods to improve health, bringing together researchers with deep expertise in statistical and computational methods and their biomedical applications.
Since 2013, the MDU has been an integral part of the MRC’s Institute of Metabolic Science, focusing on researching how metabolic health is maintained, what happens when it is disrupted, and the development of ill-health and disease.
Metabolic disorders such as obesity, insulin resistance, type 2 diabetes, fatty liver disease, and related endocrine disorders are conditions that affect all aspects of metabolism.
This study aims to help develop better treatment strategies for patients living with these types of conditions.
Jessica Boname, head of the MRC’s Division of Population and Systems Medicine, said: “Together our two departments are translating academic research into action, contributing to improving health outcomes in the UK by tackling some of the biggest health challenges we face.”
Recently, M.R.C. Partnered We have partnered with pharmaceutical company AstraZeneca to provide industry training for six MRC Clinical Fellows, helping to further advance clinical research in the UK.
Last September, MRC Invested £2 million will be invested in four research and innovation teams to better understand and treat low-survival cancers, including those of the brain, lung and oesophagus.
